BOIRF (Boiron) Valuation Rank


BOIRF Boiron SA BOIRF
62 GF Score
Price $31.90
GF Value $38.49
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Boiron Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Boiron Valuation Rank Related Terms

BOIRF
62GF Score
Boiron SA BOIRF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Boiron (BOIRF) Overvalued in 2026?

Based on GuruFocus' analysis, Boiron stock appears to be undervalued. The current stock price of $31.90 is trading 17.1% below its estimated GF Value™ of $38.49. GuruFocus considers Boiron to be Fairly Valued.

Key valuation signals for BOIRF:

  • Valuation Rank:
  • GF Value™: $38.49 vs. price of $31.90 (17.1% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boiron Business Description

Address 2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score

Get the complete analysis for BOIRF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.90
Price
$38.49
GF Value